Skip to content

MRI/Ultrasound Fusion-Guided Biopsy for Prostate Cancer

Comparison of MRI/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018575
Enrollment
Unknown
Registered
2018-09-25
Start date
2018-10-08
Completion date
Unknown
Last updated
2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:whole-gland pathology after prostatectomy
Index test:MRI image

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) Patients with clinically suspected prostate cancer; 2) PSA<20ng/ml; 3) MRI PI-RADS score =3; 4) Aged < 75 years; 5) No prior biopsy; 6) No prior ADT, radiotherapy and chemotherapy; 7) Patients volunteered to participate in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients diagnosed with prostate cancer; 2) Prior prostate cancer therapy; 3) Patients with uncontrolled infectious disease; 4) Patients with hemorrhagic tendency; 5) Patients who cannot undergo lithotomy position; 6) Patients with serious cardiovascular, cerebrovascular, pulmonary, hepatic, renal disease, or nervous system disease; 7) Patients who undergo other clinical trials; 8) Patients who cannot cooperate with investigator; 9) Contraindication to MRI; 10) Patients who are not suitable for our clinical trials.

Design outcomes

Primary

MeasureTime frame
accuracy of the targeted biopsy;

Countries

China

Contacts

Public ContactMing Liu

Beijing Hospital

liuming19731029@163.com+86 13911036970

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026